These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 17804222)

  • 1. Synthesis and antitubercular activity of lipophilic moxifloxacin and gatifloxacin derivatives.
    de Almeida MV; Saraiva MF; de Souza MV; da Costa CF; Vicente FR; Lourenço MC
    Bioorg Med Chem Lett; 2007 Oct; 17(20):5661-4. PubMed ID: 17804222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and antitubercular evaluation of new fluoroquinolone derivatives coupled with carbohydrates.
    Saraiva MF; de Souza MV; Tran Huu Dau ME; Araújo DP; de Carvalho GS; de Almeida MV
    Carbohydr Res; 2010 Apr; 345(6):761-7. PubMed ID: 20167309
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis of gatifloxacin derivatives and their biological activities against Mycobacterium leprae and Mycobacterium tuberculosis.
    Gomez C; Ponien P; Serradji N; Lamouri A; Pantel A; Capton E; Jarlier V; Anquetin G; Aubry A
    Bioorg Med Chem; 2013 Feb; 21(4):948-56. PubMed ID: 23294829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Moxifloxacin lethality against Mycobacterium tuberculosis in the presence and absence of chloramphenicol.
    Malik M; Drlica K
    Antimicrob Agents Chemother; 2006 Aug; 50(8):2842-4. PubMed ID: 16870782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibacterial activity of lipophilic fluoroquinolone derivatives.
    de Almeida CG; Diniz CG; Silva VL; Saraiva MF; Le Hyaric M; de Almeida MV
    Med Chem; 2009 Sep; 5(5):419-21. PubMed ID: 19534679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gatifloxacin, gemifloxacin, and moxifloxacin: the role of 3 newer fluoroquinolones.
    Saravolatz LD; Leggett J
    Clin Infect Dis; 2003 Nov; 37(9):1210-5. PubMed ID: 14557966
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rate of bacterial eradication by ophthalmic solutions of fourth-generation fluoroquinolones.
    Callegan MC; Novosad BD; Ramadan RT; Wiskur B; Moyer AL
    Adv Ther; 2009 Apr; 26(4):447-54. PubMed ID: 19381523
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gatifloxacin derivatives: synthesis, antimycobacterial activities, and inhibition of Mycobacterium tuberculosis DNA gyrase.
    Sriram D; Aubry A; Yogeeswari P; Fisher LM
    Bioorg Med Chem Lett; 2006 Jun; 16(11):2982-5. PubMed ID: 16554151
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro activity of fluoroquinolones against ocular bacterial isolates in São Paulo, Brazil.
    Oliveira AD; D'Azevedo PA; Francisco W
    Cornea; 2007 Feb; 26(2):194-8. PubMed ID: 17251812
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of resistance to gatifloxacin and moxifloxacin in Streptococcus pneumoniae with the VITEK 2 instrument.
    Jorgensen JH; Crawford SA; McElmeel LM; Whitney CG
    J Clin Microbiol; 2004 Dec; 42(12):5928-30. PubMed ID: 15583344
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and antitubercular activity of palladium and platinum complexes with fluoroquinolones.
    Vieira LM; de Almeida MV; Lourenço MC; Bezerra FA; Fontes AP
    Eur J Med Chem; 2009 Oct; 44(10):4107-11. PubMed ID: 19482387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibacterial activity of the fourth-generation fluoroquinolones gatifloxacin and moxifloxacin against ocular pathogens.
    Callegan MC; Ramirez R; Kane ST; Cochran DC; Jensen H
    Adv Ther; 2003; 20(5):246-52. PubMed ID: 14964344
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determination of critical concentrations of moxifloxacin and gatifloxacin for drug susceptibility testing of Mycobacterium tuberculosis in the BACTEC MGIT 960 system.
    Isaeva Y; Bukatina A; Krylova L; Nosova E; Makarova M; Moroz A
    J Antimicrob Chemother; 2013 Oct; 68(10):2274-81. PubMed ID: 23788475
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and evaluation of 1-cyclopropyl-2-thioalkyl-8-methoxy fluoroquinolones.
    Marks KR; Malik M; Mustaev A; Hiasa H; Drlica K; Kerns RJ
    Bioorg Med Chem Lett; 2011 Aug; 21(15):4585-8. PubMed ID: 21705218
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Moxifloxacin and gatifloxacin in an acid model of persistent Mycobacterium tuberculosis.
    Kubendiran G; Paramasivan CN; Sulochana S; Mitchison DA
    J Chemother; 2006 Dec; 18(6):617-23. PubMed ID: 17267339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Moxifloxacin.
    Tuberculosis (Edinb); 2008 Mar; 88(2):127-31. PubMed ID: 18486050
    [No Abstract]   [Full Text] [Related]  

  • 17. Synthesis and in vitro antitubercular activity of a series of quinoline derivatives.
    de Souza MV; Pais KC; Kaiser CR; Peralta MA; de L Ferreira M; Lourenço MC
    Bioorg Med Chem; 2009 Feb; 17(4):1474-80. PubMed ID: 19188070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro and in vivo potency of moxifloxacin and moxifloxacin ophthalmic solution 0.5%, a new topical fluoroquinolone.
    Stroman DW; Dajcs JJ; Cupp GA; Schlech BA
    Surv Ophthalmol; 2005 Nov; 50 Suppl 1():S16-31. PubMed ID: 16257308
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro antifungal activity of the fourth generation fluoroquinolones against Candida isolates from human ocular infections.
    Ozdek SC; Miller D; Flynn PM; Flynn HW
    Ocul Immunol Inflamm; 2006 Dec; 14(6):347-51. PubMed ID: 17162605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Review of third-and fourth-generation fluoroquinolones in ophthalmology: in-vitro and in-vivo efficacy.
    Scoper SV
    Adv Ther; 2008 Oct; 25(10):979-94. PubMed ID: 18836691
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.